JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB190509

Anti-FUT4 antibody [E26-A] - N-terminal

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Monoclonal FUT4 antibody. N-terminal. Suitable for IHC-P and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human FUT4.

View Alternative Names

ELFT, FCT3A, FUT4, 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase, ELAM-1 ligand fucosyltransferase, Fucosyltransferase 4, Fucosyltransferase IV, Galactoside 3-L-fucosyltransferase, Fuc-TIV, FucT-IV

1 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FUT4 antibody [E26-A] - N-terminal (AB190509)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FUT4 antibody [E26-A] - N-terminal (AB190509)

Immunohistochemical analysis of paraffin-embedded HRS cells of classical Hodgkin lymphoma labeling FUT4 with ab190509 at 1/100 dilution.

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

E26-A

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

Synthetic Peptide within Human FUT4. The exact immunogen used to generate this antibody is proprietary information.

P22083

Epitope

Antibody recognizes the epitope located between Pro28 - Gly49

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/200", "IHCP-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification notes
This immunoglobulin is the product of one single B-cell line from the crude anti-peptide polyclonal anti-serum. This antibody is purified using a propriety technique and offers a completely post-translationally modified and properly glycosylated antibody. This offers increased stability.
Storage buffer
pH: 8 Preservative: 0.05% Sodium azide Constituents: 2% BSA, 0.32% Tris HCl
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The FUT4 protein also known as fucosyltransferase 4 plays an essential role in glycosylation processes by adding fucose to glycolipids and glycoproteins. This enzyme is responsible for the synthesis of Lewis X antigens. FUT4 has a molecular mass of around 44 kDa and is expressed prominently in myeloid cells such as neutrophils and monocytes. It exhibits a significant presence in the bone marrow and expressed on the surface of certain leukocytes.
Biological function summary

The activity of FUT4 is important for cell adhesion migration and immune response modulation. It helps in the formation of selectin ligands which mediate cell-to-cell interactions through the binding of selectins on endothelial cells. FUT4 does not form a larger protein complex but interacts with substrates and cofactors to achieve its function. Its role is particularly significant in the context of inflammation and hematopoiesis.

Pathways

FUT4 is involved in the biosynthesis of glycoconjugates especially influencing the E-selectin and P-selectin pathways. These pathways are integral to leukocyte trafficking during inflammatory responses. FUT4 activity shows a functional relationship with other fucosyltransferases including FUT3 and FUT5 which also participate in modifying glycolipids and glycoproteins. This makes FUT4 a part of the larger network regulating cell-surface carbohydrate structures.

FUT4 has been linked to chronic inflammatory diseases and Leukocyte Adhesion Deficiency II. Aberrations in FUT4 expression can lead to altered selectin-mediated adhesion impacting immune cell recruitment. Additionally FUT4 involvement in cancer has attracted attention as changes in its activity can impact tumor cell metastasis. It is also worthwhile to note pathways with E-selectin can influence its disease association highlighting possible therapeutic targets in E-selectin-related disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Isoform Short. Catalyzes alpha(1->3) linkage of fucosyl moiety transferred from GDP-beta-L-fucose to N-acetyl glucosamine (GlcNAc) within type 2 lactosamine (LacNAc, Gal-beta(1->4)GlcNAc) glycan attached to N- or O-linked glycoproteins (PubMed : 1702034, PubMed : 1716630, PubMed : 29593094). Robustly fucosylates nonsialylated distal LacNAc unit of the polylactosamine chain to form Lewis X antigen (CD15), a glycan determinant known to mediate important cellular functions in development and immunity. Fucosylates with lower efficiency sialylated LacNAc acceptors to form sialyl Lewis X and 6-sulfo sialyl Lewis X determinants that serve as recognition epitopes for C-type lectins (PubMed : 1716630, PubMed : 29593094). Together with FUT7 contributes to SELE, SELL and SELP selectin ligand biosynthesis and selectin-dependent lymphocyte homing, leukocyte migration and blood leukocyte homeostasis (By similarity). In a cell type specific manner, may also fucosylate the internal LacNAc unit of the polylactosamine chain to form VIM-2 antigen that serves as recognition epitope for SELE (PubMed : 11278338, PubMed : 1716630).. Isoform Long. Does not generate Lewis X antigens.
See full target information FUT4

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 14:603 PubMed36746939

2023

LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice.

Applications

Unspecified application

Species

Unspecified reactive species

Ramachandran Prakasam,Angela Bonadiman,Roberta Andreotti,Emanuela Zuccaro,Davide Dalfovo,Caterina Marchioretti,Debasmita Tripathy,Gianluca Petris,Eric N Anderson,Alice Migazzi,Laura Tosatto,Anna Cereseto,Elena Battaglioli,Gianni Sorarù,Wooi Fang Lim,Carlo Rinaldi,Fabio Sambataro,Naemeh Pourshafie,Christopher Grunseich,Alessandro Romanel,Udai Bhan Pandey,Andrea Contestabile,Giuseppe Ronzitti,Manuela Basso,Maria Pennuto
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com